Factors associated with prolonged progression‐free survival of patients treated with first‐line afatinib for advanced epidermal growth factor receptor‐mutated non‐small cell lung cancer

Factors associated with prolonged progression‐free survival of patients treated with first‐line afatinib for advanced epidermal growth factor receptor‐mutated non‐small cell lung cancer

Abstract Background This study aimed to investigate the factors associated with prolonged progression‐free survival (PFS) (>36 months) of advanced non‐small cell lung cancer (NSCLC) patients harboring epidermal growth factor receptor (EGFR) mutations treated with first‐line afatinib. Methods We p...

Full description

Bibliographic Details
Main Authors:	Li‐Chung Chiu, Ping‐Chih Hsu, Chin‐Chou Wang, How‐Wen Ko, Scott Chih‐Hsi Kuo, Jia‐Shiuan Ju, Pi‐Hung Tung, Allen Chung‐Cheng Huang, Cheng‐Ta Yang
Format:	Article
Language:	English
Published:	Wiley 2024-03-01
Series:	Thoracic Cancer
Subjects:	afatinib epidermal growth factor receptor mutation non‐small cell lung cancer progression‐free survival
Online Access:	https://doi.org/10.1111/1759-7714.15212

Similar Items

Bilateral keratitis associated with afatinib therapy
by: Ya-Tung Liu, et al.
Published: (2024-01-01)

Epidermal Growth Factor Receptor Exon 19 Deletion Subtypes Do Not Influence Survival Outcomes Following First-line Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitors in Advanced Nonsmall Cell Lung Cancer Patients
by: Yan-Jei Tang, et al.
Published: (2024-01-01)

The difference between dacomitinib and afatinib in effectiveness and safety in first-line treatment of patients with advanced EGFR-mutant non-small cell lung cancer: a real-world observational study
by: Wen-Chien Cheng, et al.
Published: (2024-02-01)

Rebiopsy Enhances Survival with Afatinib vs. Osimertinib in EGFR Exon 19 Deletion Non-Small Cell Lung Cancer: A Multicenter Study in Taiwan
by: Jerry Shu-Hung Kuo, et al.
Published: (2025-01-01)

Successful treatment of a patient with NSCLC carrying uncommon compound L861Q/G719X epidermal growth factor receptor mutations using Afatinib
by: Zihan Zhou, et al.
Published: (2024-01-01)

Responsive afatinib treatment in high-grade salivary gland ductal carcinoma and NSCLC with uncommon EGFR mutations: Treatment outcomes
by: Sivakamavalli Jeyachandran
Published: (2024-06-01)

Afatinib-Induced Tumor Lysis Syndrome in Pulmonary Adenocarcinoma: A Case Report and Literature Review
by: Goohyeon Hong
Published: (2023-12-01)

Dermatologic Adverse Events Following Afatinib in a Woman with Non-Small-Cell Lung Cancer: A Case Report
by: Tsaqilah L, et al.
Published: (2025-01-01)

Afatinib as first-line treatment for advanced lung squamous cell carcinoma harboring uncommon EGFR G719C and S768I co-mutation: A case report and literature review
by: Ruoyu Deng, et al.
Published: (2024-08-01)

Optimal first-line treatment for EGFR-mutated NSCLC: a comparative analysis of osimertinib and second-generation EGFR-TKIs
by: Hsu-Yuan Chen, et al.
Published: (2024-10-01)

Afatinib Combined with Bevacizumab in the Treatment of Patients with Non-Small Cell Lung Cancer Harboring EGFR G719X, S768I or L861Q/P Mutations
by: Han X, et al.
Published: (2024-11-01)

Effectiveness of EGFR tyrosine kinase inhibitors in advanced non‐small cell lung cancer patients with uncommon EGFR mutations: A multicenter observational study
by: Masaki Kanazu, et al.
Published: (2021-01-01)

Modern vector in treatment of patients with lung cancer: tyrosine kinase inhibitors in epidermal growth factor receptor mutations (literature review)
by: O.M. Smorodska, et al.
Published: (2021-06-01)

Durable response to afatinib in advanced lung adenocarcinoma harboring a novel NPTN-NRG1 fusion: a case report
by: Xin Nie, et al.
Published: (2023-08-01)

Afatinib Treatment for Advanced Mixed Non-small Cell Lung Cancer  with CRISPLD2-NRG1 Fusion: A Case Report and Literature Review
by: Chunmei CHEN, et al.
Published: (2024-05-01)

Biodegradable Carbonate Apatite Nanoparticle as a Delivery System to Promote Afatinib Delivery for Non-Small Cell Lung Cancer Treatment
by: Nian N. N. Maarof, et al.
Published: (2022-06-01)

Afatinib Reverses EMT via Inhibiting CD44-Stat3 Axis to Promote Radiosensitivity in Nasopharyngeal Carcinoma
by: Huichao Huang, et al.
Published: (2022-12-01)

Metformin Enhances TKI-Afatinib Cytotoxic Effect, Causing Downregulation of Glycolysis, Epithelial–Mesenchymal Transition, and EGFR-Signaling Pathway Activation in Lung Cancer Cells
by: Pedro Barrios-Bernal, et al.
Published: (2022-03-01)

Activity of afatinib in patients with NSCLC harboring novel uncommon EGFR mutations with or without co-mutations: a case report
by: Petros Christopoulos, et al.
Published: (2024-05-01)

A real-world cohort study of first-line afatinib in patients with EGFR-mutant advanced non-small cell lung cancer in Vietnam
by: Cam Phuong Pham, et al.
Published: (2024-02-01)

An epidermal growth factor receptor compound mutation of L858R with S768I in advanced non-small-cell lung cancer: a case report
by: Sara Boukansa, et al.
Published: (2024-03-01)

OPTIMAL SEQUENCE OF APPLICATION OF EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS IN ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS WITH ACTIVATING EGFR MUTATIONS
by: A. A. Kolomeytseva, et al.
Published: (2020-12-01)

Pneumonic-type lung adenocarcinoma with KRAS G12V mutation and sustained response to Afatinib
by: Jie Zhao, et al.
Published: (2024-04-01)

Intravesical Instillation of Hyaluronic Acid With Epidermal Growth Factor for Restoring Urothelial Denudation and Alleviating Oxidative Stress in Lipopolysaccharide-Induced Interstitial Cystitis of Rats
by: Chih-Chieh Lin, et al.
Published: (2024-06-01)

Effectiveness and safety of a novel dexamethasone mouthwash formulation in managing stomatitis in cancer patients
by: Xènia Fernández-Sala, et al.
Published: (2021-01-01)

The spatial organization of the epidermal growth factor receptor on the surface of colorectal carcinoma cells
by: Fournier, C
Published: (2015)

Case report: Favorable efficacy of combined afatinib and anlotinib treatment in a lung adenocarcinoma patient harboring uncommon EGFR L858M/L861R mutations
by: Yueming He, et al.
Published: (2024-11-01)

Expression of human epidermal growth factor in pichia pastoris and optimization of fermentation conditions
by: Eissazadeh, Samira
Published: (2012)

Epidermal growth factor and remarkable correlations in a case series COVID-19
by: HÃ©ctor JosÃ© PÃ©rez HernÃ¡ndez
Published: (2024-06-01)

Platelet reserve of Epidermal Growth Factor: approach to a possible emerging concept
by: Héctor José Pérez Hernández, et al.
Published: (2024-08-01)

Hydration effects on the efficacy of the Epidermal growth factor receptor kinase inhibitor afatinib
by: Kannan, Srinivasaraghavan, et al.
Published: (2017)

The Great Mimicker: Unique Presentation of Epidermal Inclusion Cyst on the Breast
by: Isadora Linford, et al.
Published: (2024-10-01)

Association between exposure to organophosphate flame retardants and epidermal growth factor receptor expression in lung cancer patients
by: Po‐Ju Chen, et al.
Published: (2024-08-01)

Recovery and purification of epidermal growth factor from fermentation broth using expanded bed chromatography
by: Rosti, Ira Amira
Published: (2013)

Epidermal Growth Factor Modulates Fetal Thymocyte Growth and Differentiation
by: Claudia S. Freitas, et al.
Published: (1998-01-01)

Healing properties of epidermal growth factor and tocotrienol-rich fraction formulation in deep partial-thickness burn wound model
by: Guo, Hui-Fang
Published: (2017)

Epidermal growth factor dampens pro-inflammatory gene expression induced by interferon-gamma in global transcriptome analysis of keratinocytes
by: David C. Gibbs, et al.
Published: (2025-02-01)

Clinical and pathological characteristics of epidermal cysts in hairless extremities
by: LU Bo, et al.
Published: (2024-10-01)

Outcomes of the Recombinant Human Epidermal Growth Factor Addition to Chloramphenicol Ointment for Facial Burn Wound Healing
by: Pornprom Muangman, et al.
Published: (2019-11-01)

“ACHILLES” Heel No More? Afatinib at 40 Mg Once Daily is Superior to Platinum-Based Chemotherapy in EGFR Uncommon (G719X, S768I, and L861Q) Mutations (ACHILLES/TORG1834)
by: Luo FX, et al.
Published: (2024-05-01)